Kamil Paruch

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2156211/publications.pdf

Version: 2024-02-01

30	996	535685 17	511568 30
papers	citations	h-index	g-index

30	30	30	1796
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides. Journal of Medicinal Chemistry, 2022, 65, 5701-5723.	2.9	5
2	Cytoprotective activities of kinetin purine isosteres. Bioorganic and Medicinal Chemistry, 2021, 33, 115993.	1.4	6
3	Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core. European Journal of Medicinal Chemistry, 2021, 215, 113299.	2.6	12
4	Cdc-Like Kinases (CLKs): Biology, Chemical Probes, and Therapeutic Potential. International Journal of Molecular Sciences, 2020, 21, 7549.	1.8	41
5	The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxelâ€resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe. Molecular Oncology, 2020, 14, 2487-2503.	2.1	13
6	CDK12 controls G1/S progression by regulating RNAPII processivity at core DNA replication genes. EMBO Reports, 2019, 20, e47592.	2.0	64
7	Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. Haematologica, 2019, 104, 2443-2455.	1.7	23
8	Furo[3,2â€b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway. Angewandte Chemie, 2019, 131, 1074-1078.	1.6	32
9	Furo[3,2â€b]pyridine: A Privileged Scaffold for Highly Selective Kinase Inhibitors and Effective Modulators of the Hedgehog Pathway. Angewandte Chemie - International Edition, 2019, 58, 1062-1066.	7.2	38
10	EU-OPENSCREEN: A Novel Collaborative Approach to Facilitate Chemical Biology. SLAS Discovery, 2019, 24, 398-413.	1.4	12
11	Impact of the access tunnel engineering on catalysis is strictly ligandâ€specific. FEBS Journal, 2018, 285, 1456-1476.	2.2	50
12	Preparation of 3,4-Substituted-5-Aminopyrazoles and 4-Substituted-2-Aminothiazoles. Journal of Organic Chemistry, 2018, 83, 15380-15405.	1.7	16
13	Structural Basis of the Interaction of Cyclinâ€Dependent Kinaseâ€…2 with Roscovitine and Its Analogues Having Bioisosteric Central Heterocycles. ChemPhysChem, 2017, 18, 785-795.	1.0	14
14	Diastereoselective Flexible Synthesis of Carbocyclic C-Nucleosides. Journal of Organic Chemistry, 2017, 82, 3382-3402.	1.7	8
15	Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation. Molecular Cancer Therapeutics, 2017, 16, 1831-1842.	1.9	17
16	Explicit treatment of active-site waters enhances quantum mechanical/implicit solvent scoring: Inhibition of CDK2 by new pyrazolo[1,5-a]pyrimidines. European Journal of Medicinal Chemistry, 2017, 126, 1118-1128.	2.6	32
17	BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors. Tumor Biology, 2017, 39, 101042831772747.	0.8	28
18	Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells. Neoplasia, 2017, 19, 830-841.	2.3	29

#	Article	IF	Citations
19	A Concise Synthesis of Forskolin. Angewandte Chemie, 2017, 129, 12760-12763.	1.6	3
20	A Concise Synthesis of Forskolin. Angewandte Chemie - International Edition, 2017, 56, 12586-12589.	7.2	16
21	Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells. Oncotarget, 2016, 7, 62091-62106.	0.8	19
22	Syntheses of 5â€²-amino-2â€²,5â€²-dideoxy-2â€²,2â€²-difluorocytidine derivatives as novel anticancer nucleoside analogs. Tetrahedron Letters, 2014, 55, 598-602.	0.7	6
23	New carbocyclic nucleosides: synthesis of carbocyclic pseudoisocytidine and its analogs. Tetrahedron Letters, 2014, 55, 3713-3716.	0.7	8
24	Discovery of pyrazolo[1,5-a]pyrimidine-based Pim inhibitors: A template-based approach. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6178-6182.	1.0	27
25	Quantum Mechanical Scoring: Structural and Energetic Insights into Cyclin-Dependent Kinase 2 Inhibition by Pyrazolo[1,5-a]pyrimidines. Current Computer-Aided Drug Design, 2013, 9, 118-129.	0.8	52
26	Cyclin-dependent kinase Inhibitors Inspired by Roscovitine: Purine Bioisosteres. Current Pharmaceutical Design, 2012, 18, 2974-2980.	0.9	55
27	Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening. Molecular Cancer Therapeutics, 2011, 10, 591-602.	1.9	155
28	Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases. ACS Medicinal Chemistry Letters, 2010, 1, 204-208.	1.3	134
29	Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6220-6223.	1.0	49
30	Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6216-6219.	1.0	32